VCI Wealth Management LLC Takes Position in Colgate-Palmolive (NYSE:CL)

VCI Wealth Management LLC bought a new stake in shares of Colgate-Palmolive (NYSE:CL) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,920 shares of the company’s stock, valued at approximately $870,000.

Other hedge funds have also modified their holdings of the company. &PARTNERS raised its position in Colgate-Palmolive by 0.7% in the 4th quarter. &PARTNERS now owns 17,643 shares of the company’s stock valued at $1,406,000 after purchasing an additional 129 shares during the last quarter. West Branch Capital LLC raised its position in Colgate-Palmolive by 24.0% in the 4th quarter. West Branch Capital LLC now owns 682 shares of the company’s stock valued at $54,000 after purchasing an additional 132 shares during the last quarter. First Foundation Advisors raised its position in Colgate-Palmolive by 2.7% in the 3rd quarter. First Foundation Advisors now owns 5,226 shares of the company’s stock valued at $372,000 after purchasing an additional 136 shares during the last quarter. Waldron Private Wealth LLC raised its position in shares of Colgate-Palmolive by 2.7% during the third quarter. Waldron Private Wealth LLC now owns 5,361 shares of the company’s stock worth $381,000 after acquiring an additional 140 shares during the last quarter. Finally, Autumn Glory Partners LLC raised its position in shares of Colgate-Palmolive by 2.7% during the fourth quarter. Autumn Glory Partners LLC now owns 5,319 shares of the company’s stock worth $424,000 after acquiring an additional 140 shares during the last quarter. 80.41% of the stock is owned by hedge funds and other institutional investors.

Colgate-Palmolive Stock Up 0.5 %

Shares of CL stock traded up $0.40 on Thursday, hitting $89.27. 6,361,812 shares of the stock were exchanged, compared to its average volume of 4,572,863. The company has a current ratio of 1.11, a quick ratio of 0.71 and a debt-to-equity ratio of 8.59. The firm has a market capitalization of $73.38 billion, a P/E ratio of 31.97, a price-to-earnings-growth ratio of 3.33 and a beta of 0.42. The business has a 50-day moving average of $87.40 and a 200 day moving average of $81.25. Colgate-Palmolive has a fifty-two week low of $67.62 and a fifty-two week high of $90.37.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, January 26th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.02. The company had revenue of $4.95 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Colgate-Palmolive had a return on equity of 509.75% and a net margin of 11.82%. Colgate-Palmolive’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.77 earnings per share. Equities analysts anticipate that Colgate-Palmolive will post 3.5 EPS for the current year.

Colgate-Palmolive Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 22nd will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.24%. The ex-dividend date of this dividend is Friday, April 19th. This is a positive change from Colgate-Palmolive’s previous quarterly dividend of $0.48. Colgate-Palmolive’s dividend payout ratio is presently 71.94%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CL shares. Stifel Nicolaus boosted their target price on Colgate-Palmolive from $89.00 to $94.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. JPMorgan Chase & Co. boosted their target price on Colgate-Palmolive from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, January 18th. Wells Fargo & Company boosted their target price on Colgate-Palmolive from $80.00 to $88.00 and gave the stock an “equal weight” rating in a research report on Monday, January 29th. UBS Group boosted their target price on Colgate-Palmolive from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, January 29th. Finally, StockNews.com cut Colgate-Palmolive from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $89.50.

Insider Buying and Selling

In related news, CEO Noel R. Wallace sold 29,772 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $84.06, for a total transaction of $2,502,634.32. Following the sale, the chief executive officer now owns 301,343 shares in the company, valued at $25,330,892.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Colgate-Palmolive news, Director C Martin Harris sold 2,760 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $84.50, for a total value of $233,220.00. Following the sale, the director now owns 19,272 shares in the company, valued at $1,628,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Noel R. Wallace sold 29,772 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $84.06, for a total value of $2,502,634.32. Following the completion of the sale, the chief executive officer now owns 301,343 shares in the company, valued at approximately $25,330,892.58. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 232,371 shares of company stock worth $19,505,099. Corporate insiders own 0.34% of the company’s stock.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.